EXTRACT OF THE FINANCIAL RESULTS - 30.06.2025 PUBLISHED IN INDIAN EXPRESS - ENGLISH EDITION AND FINANCIAL EXPRESS - GUJARATI EDITION DATED 14.08.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanza Biosciences Ltd informed BSE that the extract of its unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 was published in Indian Express (English) and Financial Express (Gujarati) on 14 August 2025, as required under SEBI LODR Regulation 47. Consolidated total income from operations jumped sharply to Rs 895.66 lacs in Q1 FY26 from just Rs 52.91 lacs in Q1 FY25. The company swung back to a consolidated net profit after tax of Rs 8.70 lacs, compared with a loss of Rs 99.81 lacs in the year-ago quarter. On a standalone basis, total income rose to Rs 783.81 lacs from Rs 18.89 lacs, with a small profit after tax of Rs 1.86 lacs versus a loss of Rs 96.54 lacs earlier. Basic and diluted EPS on a consolidated basis improved to Rs 0.02 from Rs -0.25, though the equity share capital remained unchanged at Rs 400 lacs.
The sharp year-on-year revenue jump and return to profitability could lift sentiment, but results are unaudited and the absolute profit is small relative to revenue, so the stock is unlikely to see a sustained move without follow-up quarters confirming the trend.